Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases

Treatment strategies for colorectal cancer liver metastasis (CRCLM) such as major hepatectomy and portal vein embolization (PVE) rely on liver regeneration. We aim to investigate the effect of neoadjuvant chemotherapy on liver regeneration occurring after PVE and after major hepatectomy.

[1]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[2]  K. Brown,et al.  Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. , 2013, JAMA surgery.

[3]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[4]  L. Spelt,et al.  Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  G. Wakabayashi,et al.  Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume , 2013, World Journal of Surgical Oncology.

[6]  G. Fürst,et al.  In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two‐stage liver resection , 2013, The British journal of surgery.

[7]  E. J. van der Jagt,et al.  Early hepatic regeneration index and completeness of regeneration at 6 months after partial hepatectomy , 2012, The British journal of surgery.

[8]  M. Aljiffry,et al.  Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[9]  R. Adam,et al.  Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non‐resectable) limit? , 2010, Journal of surgical oncology.

[10]  C. Sturesson,et al.  Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  I. Endo,et al.  Influence of Chemotherapy on Liver Regeneration Induced by Portal Vein Embolization or First Hepatectomy of a Staged Procedure for Colorectal Liver Metastases , 2010, Journal of Gastrointestinal Surgery.

[12]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[13]  T. Pawlik,et al.  Current management of colorectal hepatic metastasis , 2009, Expert review of gastroenterology & hepatology.

[14]  L. Ellis,et al.  Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Hainsworth,et al.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Vauthey,et al.  Standardized Liver Volumetry for Portal Vein Embolization , 2008, Seminars in interventional radiology.

[17]  L. Schwartz,et al.  Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases , 2008, Annals of surgery.

[18]  E. Abdalla,et al.  Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome , 2007, The British journal of surgery.

[19]  R. Greil,et al.  Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Abdalla,et al.  Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement , 2006, Annals of Surgical Oncology.

[21]  R. Hutchins,et al.  Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. , 2006, The British journal of radiology.

[22]  V. Vilgrain,et al.  Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction , 2006, Journal of Gastrointestinal Surgery.

[23]  S. Curley,et al.  Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Strasberg,et al.  Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. , 2005, Journal of hepato-biliary-pancreatic surgery.

[25]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[27]  N. Selzner,et al.  Liver regeneration after adult living donor and deceased donor split‐liver transplants , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  F. Lévi,et al.  Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver , 2003, The British journal of surgery.

[30]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Yamanaka,et al.  Multivariate analysis of liver regenerative capacity after hepatectomy in humans , 1997 .

[32]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[33]  J. Fujimoto,et al.  Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function , 1993, Hepatology.

[34]  N. Nagasue,et al.  Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. , 1987, Annals of surgery.

[35]  C. Dejong,et al.  Influence of Preoperative Chemotherapy on CT Volumetric Liver Regeneration Following Right Hemihepatectomy , 2013, World Journal of Surgery.

[36]  N. Fausto,et al.  Liver regeneration. , 2012, Journal of hepatology.

[37]  J. Vauthey,et al.  [Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?]. , 2010, Journal de chirurgie.

[38]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.